Cargando…

Clinical significance of Janus Kinase inhibitor selectivity

Mostrar otras versiones (1)

Detalles Bibliográficos
Autor principal:	Choy, Ernest H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532441/ https://www.ncbi.nlm.nih.gov/pubmed/30698756 http://dx.doi.org/10.1093/rheumatology/kez002

Ejemplares similares

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Corrigendum: Analgesic effect of AG490, a Janus kinase inhibitor, on oxaliplatin-induced acute neuropathic pain
Publicado: (2019)

Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer
por: Kumar, J, et al.
Publicado: (2015)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis
por: Ding, Yuchuan, et al.
Publicado: (2021)

Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012)

Janus Kinase Inhibitors and Cell Therapy
por: Assal, Amer, et al.
Publicado: (2021)

Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors
por: Zhong, Haizhen A., et al.
Publicado: (2023)

Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: Lefevre, Pavine L C, et al.
Publicado: (2020)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2018)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations
por: Hu, S, et al.
Publicado: (2017)

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
por: Chimalakonda, Anjaneya, et al.
Publicado: (2021)

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
por: Veale, Douglas J, et al.
Publicado: (2019)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
por: Słuczanowska-Głąbowska, Sylwia, et al.
Publicado: (2021)

Janus kinase inhibitors in autoimmune bullous diseases
por: Huang, Dawei, et al.
Publicado: (2023)

Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors (Review)
por: Umene, Kiyoko, et al.
Publicado: (2019)

Kinase inhibitors fail to induce mesenchymal-epithelial transition in fibroblasts from fibrotic lung tissue
por: Xu, Xuefeng, et al.
Publicado: (2020)

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors
por: Knight, Emily A., et al.
Publicado: (2015)

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: De Vries, L.C.S., et al.
Publicado: (2017)

Role of janus kinase inhibitors in the treatment of alopecia areata
por: Triyangkulsri, Korn, et al.
Publicado: (2018)

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
por: Qi, Fei, et al.
Publicado: (2021)

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
por: Nash, David, et al.
Publicado: (2022)

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
por: Núñez, Paulina, et al.
Publicado: (2023)

Molecular Epidemiology And Clinical Significance Of Corynebacterium Striatum Isolated From Clinical Specimens [Corrigendum]
Publicado: (2019)

Corrigendum to “Expression of HE4 in Endometrial Cancer and Its Clinical Significance”
por: Li, Xiao, et al.
Publicado: (2018)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Janus Kinases in Leukemia
por: Raivola, Juuli, et al.
Publicado: (2021)

Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
por: Mohlin, Sofie, et al.
Publicado: (2020)

Corrigendum: Glycogen synthase kinase-3β inhibitor SB216763 promotes DNA repair in ischemic retinal neurons
Publicado: (2021)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment [Corrigendum]
Publicado: (2021)

The Proton Pump Inhibitor Non-Responder: A Clinical Conundrum
por: Hussain, Zilla H, et al.
Publicado: (2015)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
por: Singer, Jack W, et al.
Publicado: (2016)

Clinical Significance of Body Fat Distribution in Coronary Artery Calcification Progression in Korean Population
por: Lee, Heesun, et al.
Publicado: (2021)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
por: Blume-Peytavi, Ulrike, et al.
Publicado: (2015)

Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors
por: Garrido-Trigo, Alba, et al.
Publicado: (2020)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
por: Chen, Miao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4uqdij7g8d6k1pggkvdr6jo6nd